Bill · H.R. 1672· House(119-HR-1672)

Maintaining Investments in New Innovation Act

Age: 55 years

North Carolina

Introduced: 2/27/2025
Last activity: 2/27/2025 — Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sponsored by: Donald Davis
Cosponsors: - 7 - 44

Health

Introduced
In Committee

What this bill would do

This bill is called the Maintaining Investments in New Innovation Act. It amends title XI of the Social Security Act. The main goal of the bill is to protect access to genetically targeted technologies. It changes the definition and timeline for certain qualifying single source drugs. Specifically, it adds an 11-year timeline for advanced drug products.

Yes· 3 of 4

Would business owners be better off under this?+5
Pharmaceutical companies developing advanced drug products benefit from increased periods of market exclusivity.
Is this likely to grow the economy?+3
The extension of market exclusivity for advanced drug products incentivizes investment in new medical technologies.
Does this put more money into scientific research?+2
The bill promotes medical innovation by providing longer exclusivity for drugs using gene-modulating technologies.

The opposite

Does this lower the price of prescription medicines?-4
Extending exclusivity periods from 7 to 11 years delays the entry of cheaper generic or biosimilar competitors into the market.
Would households on low incomes be better off under this?-2
Delayed competition from generics due to extended exclusivity may keep medication prices higher for longer.